Plain-English translation of NCT07400653 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Obesity research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing a new medication called MET097 (also known as ) designed to help adults with obesity or overweight and type 2 diabetes lose weight and improve their blood sugar control. You would give yourself a weekly injection under the skin, similar to other diabetes medications. Researchers will compare how well this medication works compared to a placebo (a shot with no active medicine) to see if it's safe and effective.
Many people with type 2 diabetes struggle to lose weight and manage their blood sugar, even with diet, exercise, and current medications. This trial is testing whether this new medication can help address both problems at once by offering a once-weekly option that may be easier to use than daily pills.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either the new medication or a placebo injection once per week that you give yourself at home. You will visit the research clinic about 14 times and have 5 phone calls over about 21 months. At these visits, you will have blood tests, weight checks, and check-ins with the research team to monitor how the treatment is working and any side effects. About two-thirds of participants will receive the actual medication, and one-third will receive placebo.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States